Prevention of thrombosis in polycythemia vera and essential thrombocythemia

Raffaele Landolfi, Leonardo Di Gennaro

Risultato della ricerca: Contributo in rivistaArticolo in rivista

36 Citazioni (Scopus)

Abstract

Identifying the most safe and effective strategy for reducing the vascular risk of subjects with polycythemia vera and essential thrombocythemia has always been challenging. The mechanisms underlying the thrombotic diathesis of these patients are still largely elusive and, more importantly, the number of large scale studies performed in this specific setting is very limited. Thus, physicians have to rely on approximate and largely subjective estimations of the vascular risk and on consensus-based recommendations. Not surprisingly, the use of several agents is quite heterogeneous among different countries. The European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP), which was established to test the efficacy and safety of low-dose aspirin in polycythemia vera, involved 12 European countries.1 The participating centers, although with moderate differences among centers and countries, prescribed hydroxyurea and aspirin to a much higher percentage of their patients than that reported in a survey on polycythemia vera treatments performed in the same years among North American centers.2 After the ECLAP trial, the recommendations on the use of aspirin in polycythemia vera will likely become more uniform but debates on hydroxyurea will probably continue for a long time. In fact, a clinical trial comparing the long-term efficacy and safety of this agent with that of alternative cytoreductive strategies would be very difficult to organize
Lingua originaleEnglish
pagine (da-a)331-335
Numero di pagine5
RivistaHaematologica
Volume93
DOI
Stato di pubblicazionePubblicato - 2008

Keywords

  • Arterial Occlusive Diseases
  • Janus Kinase 2
  • Polycythemia Vera
  • Thrombocythemia, Essential
  • Thrombophilia
  • Thrombosis
  • Venous Thrombosis

Fingerprint Entra nei temi di ricerca di 'Prevention of thrombosis in polycythemia vera and essential thrombocythemia'. Insieme formano una fingerprint unica.

Cita questo